BioCentury | May 18, 2020
Product Development

Preclinical data suggest Oxford vaccine could reduce COVID-19 symptoms, won’t provide herd immunity

Preclinical data from a leading COVID-19 vaccine candidate from Oxford University suggest that it may be more like the flu vaccine than the smallpox jab, reducing the severity of symptoms but not preventing infection. Such...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

The U.K.'s NICE said Gillian Leng will become chief executive, effective April 1, succeeding Andrew Dillon, who is stepping down. Leng was NICE's deputy chief executive and director of health and social care. Separately, the...
BioCentury | Mar 9, 2020
Deals

Lonza ‘cocoons’ give academics route to scale autologous cell therapies

A deal granting academics access to Lonza’s automated manufacturing pods could ramp up patient access to next-generation autologous cell therapies. In the long term, widespread adoption of such decentralized patient-scale technologies could help redefine modalities...
BioCentury | Mar 7, 2020
Translation in Brief

Repurposing a protease inhibitor for COVID-19; plus City of Hope’s scorpion venom CAR T and Blaze’s tech for tissue-targeted steroid delivery

Protease inhibitor blocks COVID-19 viral fusion  Camostat mesylate, a TMPRSS2 inhibitor already approved in Japan for digestive system indications, has become one of the latest drugs that could be repurposed to treat COVID-19. A team...
BC Extra | Jan 8, 2020
Company News

Management tracks: Fred Hutch taps BMS CSO Lynch; plus GSK, Rubius, Provention, Antengene, Revitope, Compugen, Wellington, Adamas, Arcturus and Turnstone

Fred Hutchinson Cancer Research Center hired Thomas Lynch as president and director, effective next month. Lynch was CSO of Bristol-Myers Squibb Co. (NYSE:BMY). He succeeds Gary Gilliland, who announced in September his plans to step...
BC Innovations | Oct 10, 2019
Distillery Therapeutics

Inhibiting translation initiation for androgen receptor-deficient prostate cancer

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer Disrupting the eIF4F translation initiation complex formation could treat androgen receptor-deficient prostate cancers. Low expression of the translation inhibitor e1F4EBP1, which when hypophosphorylated prevents eIF4F complex formation, correlated with...
BC Extra | Oct 10, 2019
Company News

bluebird tech to jump-start Novo in gene editing for hemophilia

A deal with bluebird bio is the latest move in Novo Nordisk’s push to remake its R&D, this time by partnering to develop a gene therapy for hemophilia A. The deal comes as sales for...
BC Extra | Oct 1, 2019
Company News

ElevateBio launches HighPassBio with TCR immunotherapy focus

Less than five months after its launch, ElevateBio has announced a second portfolio company: HighPassBio, which is developing T cell immunotherapies based on research from the Fred Hutchinson Cancer Research Center. HighPassBio’s lead candidate is...
BioCentury | Jul 13, 2019
Tools & Techniques

Broadening role for external control arms in clinical trials

External control arms are moving from theory to practice as drug developers begin to use them to make internal go/no-go decisions for clinical programs and to support regulatory applications. The field is largely split between...
BC Extra | Jun 28, 2019
Financial News

IPO window wide open: BridgeBio leads new listings with year’s largest

Four companies have debuted with upsized NASDAQ offerings in the past 24 hours, including the year's largest, to continue June's torrid IPO pace as 1H19 draws to a close. BridgeBio, Adaptive and Morphic all saw...
Items per page:
1 - 10 of 194
BioCentury | May 18, 2020
Product Development

Preclinical data suggest Oxford vaccine could reduce COVID-19 symptoms, won’t provide herd immunity

Preclinical data from a leading COVID-19 vaccine candidate from Oxford University suggest that it may be more like the flu vaccine than the smallpox jab, reducing the severity of symptoms but not preventing infection. Such...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

The U.K.'s NICE said Gillian Leng will become chief executive, effective April 1, succeeding Andrew Dillon, who is stepping down. Leng was NICE's deputy chief executive and director of health and social care. Separately, the...
BioCentury | Mar 9, 2020
Deals

Lonza ‘cocoons’ give academics route to scale autologous cell therapies

A deal granting academics access to Lonza’s automated manufacturing pods could ramp up patient access to next-generation autologous cell therapies. In the long term, widespread adoption of such decentralized patient-scale technologies could help redefine modalities...
BioCentury | Mar 7, 2020
Translation in Brief

Repurposing a protease inhibitor for COVID-19; plus City of Hope’s scorpion venom CAR T and Blaze’s tech for tissue-targeted steroid delivery

Protease inhibitor blocks COVID-19 viral fusion  Camostat mesylate, a TMPRSS2 inhibitor already approved in Japan for digestive system indications, has become one of the latest drugs that could be repurposed to treat COVID-19. A team...
BC Extra | Jan 8, 2020
Company News

Management tracks: Fred Hutch taps BMS CSO Lynch; plus GSK, Rubius, Provention, Antengene, Revitope, Compugen, Wellington, Adamas, Arcturus and Turnstone

Fred Hutchinson Cancer Research Center hired Thomas Lynch as president and director, effective next month. Lynch was CSO of Bristol-Myers Squibb Co. (NYSE:BMY). He succeeds Gary Gilliland, who announced in September his plans to step...
BC Innovations | Oct 10, 2019
Distillery Therapeutics

Inhibiting translation initiation for androgen receptor-deficient prostate cancer

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer Disrupting the eIF4F translation initiation complex formation could treat androgen receptor-deficient prostate cancers. Low expression of the translation inhibitor e1F4EBP1, which when hypophosphorylated prevents eIF4F complex formation, correlated with...
BC Extra | Oct 10, 2019
Company News

bluebird tech to jump-start Novo in gene editing for hemophilia

A deal with bluebird bio is the latest move in Novo Nordisk’s push to remake its R&D, this time by partnering to develop a gene therapy for hemophilia A. The deal comes as sales for...
BC Extra | Oct 1, 2019
Company News

ElevateBio launches HighPassBio with TCR immunotherapy focus

Less than five months after its launch, ElevateBio has announced a second portfolio company: HighPassBio, which is developing T cell immunotherapies based on research from the Fred Hutchinson Cancer Research Center. HighPassBio’s lead candidate is...
BioCentury | Jul 13, 2019
Tools & Techniques

Broadening role for external control arms in clinical trials

External control arms are moving from theory to practice as drug developers begin to use them to make internal go/no-go decisions for clinical programs and to support regulatory applications. The field is largely split between...
BC Extra | Jun 28, 2019
Financial News

IPO window wide open: BridgeBio leads new listings with year’s largest

Four companies have debuted with upsized NASDAQ offerings in the past 24 hours, including the year's largest, to continue June's torrid IPO pace as 1H19 draws to a close. BridgeBio, Adaptive and Morphic all saw...
Items per page:
1 - 10 of 194